Illumina’s selection for a Singapore healthcare initiative is the day’s company-specific catalyst. But the headline doesn’t explain the program’s terms or Illumina’s role.
A November 4 headline says Illumina was selected to help bring precision medicine into everyday healthcare in Singapore. It doesn’t name the organization that made the selection, describe Illumina’s work, or disclose the program’s financial value. ILMN.US shares closed at US$209.36, down 4.90% for the day.
Investor takeaway: The selection is part of a stated healthcare initiative, but the headline alone doesn’t show what it could mean for Illumina’s business.
Illumina Inc
ILMN.US
ILMN.US
Illumina Inc
WealthAwesomeMarket cap
$34.25B
P/E
39.0x
52W high
$309.35
52W low
$112.65
1W change
-21.56%
Beta
1.45
Analyst Price Targets
Based on 21 analysts covering ILMN · as of Nov 2, 2026
Wall Street analysts forecast ILMN stock price to rise 15.5% over the next 12 months.
Consensus
Hold3.48 / 5.00
Avg. Target
C$261.60
+15.5% Upside
Previously C$248.90 on Oct 26, 2026
Current Price
C$226.54
Last close
Analyst Breakdown (21 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ILMN's historical volatility
30-Day Vol
82.3%
Annualized
90-Day Vol
60.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$270.83
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$240.43 | C$181.02 – C$319.35 |
| 60 trading days | C$255.18 | C$170.81 – C$381.22 |
| 90 trading days | C$270.83 | C$165.65 – C$442.80 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Illumina closed at US$209.36
Shares fell 4.90% on the day. Trading volume was 1,435,188 shares, below the 20-day average of 2,305,640.
Bull case
The announcement links Illumina to an effort to expand precision medicine in Singapore, a potential use for its genomics work.
Bear case
The headline doesn’t disclose a contract value, timeline, expected revenue, or Illumina’s responsibilities. The business impact remains unclear.
What happened: Illumina selected for a Singapore healthcare effort
The November 4 headline says Illumina was selected to help bring precision medicine into everyday healthcare in Singapore. It doesn’t identify the organization that selected Illumina or say whether the effort involves a government program, a healthcare provider, or another initiative. It also doesn’t specify what Illumina would provide, such as sequencing services or equipment.
A separate November 3 headline mentions a Singapore genome-sequencing program covering 450,000 people. The available information doesn’t explain the program’s terms or confirm whether it’s connected to the November 4 announcement. You can find company information on the Illumina stock page, but the headline alone doesn’t establish a financial commitment.
What the numbers show: shares fell on the day
Illumina closed at US$209.36, down 4.90% for the day. Shares fell 21.56% over one week and 22.86% over one month, but remained up 68.62% year to date. Volume was 1,435,188 shares, below the 20-day average of 2,305,640.
These figures provide share-price context. The available information doesn’t show that the Singapore selection caused the daily decline. The close was below the 50-day moving average of US$249.74 and above the 200-day average of US$176.99. Illumina’s reported market capitalization was about US$34.3 billion, and its trailing P/E was 38.99. More company data is available on the ILMN stock page.
What to watch next: details that could clarify the impact
The announcement’s business significance depends on details the headline leaves out: who selected Illumina, the scope and duration of its role, and whether the work has a disclosed contract value or expected revenue contribution. More information could also clarify whether the selection is connected to the separately reported 450,000-person sequencing program.
Until those details emerge, the announcement shows that Illumina was selected for a precision-medicine effort in Singapore. It doesn’t provide enough information to estimate the effect on the company’s results.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
